December 13, 2021

IMMUNOLOGY

# Anti-Phospholipase A2 Receptor (PLA2R)

**Date effective:** January 4, 2022

**Background Information:**

The Shared Health Immunology Laboratory at St Boniface Hospital is pleased to announce the introduction of the first of two new tests for the diagnosis of Primary Membranous Nephropathy - Idiopathic Membranous Glomerulonephritis.
Our laboratory strives to provide efficient, reliable, and high-quality services that contribute to enhanced patient care. By providing this service in-house we can ensure testing is performed on fresher samples resulting in more accurate interpretation and reduce turn-around times to assist in earlier diagnosis and treatment.

**Clinical Practice Change:**

Previously referred to Mitogen Dx in Alberta, testing will now be performed by the Immunology Lab at St. Boniface Hospital using an indirect Immunofluorescence assay (IFA). Serum samples are initially screened at a 1:10 dilution utilizing slides coated with transfected cells. This test provides semiquantitative in vitro determination of human antibodies of immunoglobulin classes IgG against phospholipase A2 receptor (PLA2R) in patient samples to support the diagnosis of primary membranous nephropathy. The indirect immunofluorescence assay (IFA) is the preferred method for diagnosis due to its increased sensitivity.
A significant titre increase, decrease or disappearance precedes a change in the clinical status. Thus, the quantitative determination has a high predictive value with respect to clinical remission or relapse and risk estimation after kidney transplantation. The success of therapy can be assessed by means of the anti-PLA2R titre.

*****Testing will be restricted to Nephrologists or via prior approval*****

**References/Resources:**

| | |
|---|---|
| Test: | ANTI-PHOSPHOLIPASE A2 RECEPTOR (PLA2R) |
| Delphic Code: | PLA2 |
| Sample: | Serum 1.0 ml |
| Normal Range: | <1:10 Titre (Negative) |
| Availability: | Weekdays (5-7day TAT) |
| Requisition: | Immunology Autoimmune Laboratory Requisition<br>The Immunology Autoimmune Test Requisition will reflect these changes in the next version. Please request test in the Clinical Information/Diagnosis section of the requisition. |

**Patient Impact:**

- TAT reduced from 14+ days

**System Improvements:**

- Improved sustainability
- Decreased operating costs

**Contact Information:**

- Dr. Ping Sun, Hematopathologist, Medical Director Hematology & Immunology, Shared Health Manitoba, (phone: 204-787-4682) psun@sharedhealthmb.ca
- Jason Warren, Immunology Technical Manager, Shared Health Manitoba, (phone: 204-787-3407) jwarren3@sharedhealthmb.ca